Multi-context modeling of driver pathways reveals common and specific mechanisms across 23 cancer types
Fig 2
Results of the reliability test and regional differences in signaling pathways.
(A) The hypergeometric test reveals significant results for six types of cancer with IntOGen genes in each cohort, which investigates the overlap between cohorts’ common genes identified by IntOGen and EntCDP. The size of the circles corresponds to the significance level. Different colors in the bar graph present different features of genes identified by EntCDP: dark (light) purple indicates common genes obtained from all (part of) selected cohorts by IntOGen; yellow (pink) denotes non-IntOGen genes of any selected cohort that have (not) been verified as drivers in the literature. (B) Specific pathways of patients with a certain cancer type coming from one country (left) relative to other counties (right, denoted by colorful circles). The gray-filled bar for each signaling pathway indicates the proportion of identified genes enriched in that pathway, as shown by the ratio on the right. (C, D) Common signaling pathways among, and pathways specific to, patients with breast adenocarcinoma from the United States versus those from European Union countries and Britain (C), or with bladder cancer from the United States versus China (D). The dashed line indicates no significant results. The bar above clearly lists the names of genes with different characteristics from (A). *1: COADREAD, colorectal cancer; *2: Transcriptional misregulation in cancer; *3: Apoptotic pathways in synovial fibroblasts.